Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.380
-0.030 (-2.13%)
At close: Apr 2, 2026, 4:00 PM EDT
1.380
0.00 (-0.01%)
After-hours: Apr 2, 2026, 7:25 PM EDT
Akebia Therapeutics Revenue
In the year 2025, Akebia Therapeutics had annual revenue of $236.20M with 47.46% growth. Akebia Therapeutics had revenue of $57.62M in the quarter ending December 31, 2025, with 23.93% growth.
Revenue (ttm)
$236.20M
Revenue Growth
+47.46%
P/S Ratio
1.57
Revenue / Employee
$1,217,505
Employees
194
Market Cap
369.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 236.20M | 76.02M | 47.46% |
| Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
| Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
| Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
| Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
| Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
| Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
| Dec 31, 2018 | 207.74M | 26.52M | 14.63% |
| Dec 31, 2017 | 181.23M | 179.69M | 11,706.32% |
| Dec 31, 2016 | 1.54M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 742.90M |
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 403.14M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Canopy Growth | 203.04M |
| Kamada | 180.46M |
| Anika Therapeutics | 112.82M |
AKBA News
- 14 hours ago - Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript - Seeking Alpha
- 14 hours ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 day ago - Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - GlobeNewsWire
- 14 days ago - Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - GlobeNewsWire
- 24 days ago - Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 4 weeks ago - Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - GlobeNewsWire